Diabetes Mellitus, Type 2
Conditions
Keywords
Continuum of care, Diabetes, Pre-diabetes
Brief summary
The study aims to improve diabetes prevention, access to care and advocacy through a novel cost-effective nurse-led continuum of care approach that incorporates diabetes prevention, awareness, screening and management for low-income settings, and furthermore utilizes the endeavor to advocate for establishing standard diabetes program in Nepal.
Detailed description
The purpose of this study will be to improve diabetes prevention, access to care and advocacy through a novel cost-effective nurse-led continuum of care approach that incorporates diabetes prevention, awareness, screening and management for low-income settings, and furthermore utilizes the endeavor to advocate for establishing standard diabetes program in Nepal. We will conduct a two-arm, open-masked stratified cluster randomized controlled trial of a NUrse-led COntinuum of care for people with diabetes and pre-diabetes (NUCOD), with primary care centers (Outreach centers and Government health posts) as a unit of randomization. NUCOD will be delivered through the trained diabetes nurses in the community to the intervention group and the outcomes will be compared to the enhanced usual-treatment group at 6 and 12 months of the intervention. The primary outcome will be change in glycated hemoglobin (HbA1c) level among diabetes and progression to type 2 diabetes among pre-diabetes, and implementation outcomes measured using the RE-AIM (reach, effectiveness, adoption, implementation, and maintenance) framework. Outcomes will be analyzed on an intention to treat basis. The results of this trial will provide information about the effectiveness of the NUCOD program in improving clinical outcomes for diabetes and pre-diabetes individuals, and implementation outcomes for the organization.
Interventions
BEHAVIORALNurse-led Continuum of Care
This will be a nurse-led community level prevention program for individuals with diabetes and pre-diabetes, where participants in intervention group will receive nurse-led continuum of care while control group will receive usual diabetic care.
Sponsors
Kathmandu University School of Medical Sciences
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Caregiver, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* with confirmed pre-existing type II diabetes and prediabetes at the time of our screening (i.e., pre-existing diabetes or prediabetes) * with confirmed diagnosis of type II diabetes or prediabetes after our community screening process (i.e., newly diagnosed diabetes and prediabetes) * is not planning to relocate outside of the current place of living in next 2 years * is older than 18 years of age
Exclusion criteria
* are not psychologically capable of communication * are diagnosed as type 1 diabetes
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Glycated Hemoglobin (HbA1c) level | Baseline, 6 months, 12 months | The HbA1c will be measured using Boronate affinity chromatography (Axis-Shield, Norway) |
| Change in the incidence of diabetes among individuals with pre-diabetes | 6 months, 12 months | Electronic Health Record will be used to measure the incidence of diabetes |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Body Mass Index | Baseline, 6 months, 12 months | Body Mass Index will be calculated as weight in kilograms divided by height in meters squared |
| Change in the Reach of people participating in the program | 6 months, 12 months | Reach will be measured by the number of people participating in the program divided by the number of people eligible to be recruited into the program |
| Change in Blood Pressure | Baseline, 6 months, 12 months | The blood pressure will be measured using mean of three measurements of systolic and diastolic blood pressure, using a Microlife automatic blood pressure measuring device |
| Change in the Adoption at the patient level measured by the Diabetes Treatment Satisfaction Questionnaire | Baseline, 6 months, 12 months | The Diabetes Treatment Satisfaction Questionnaire will be used to measure patient perception of the treatment. It is composed of eight questions, each of which is scored by patients on a scale ranging from zero (e.g., very dissatisfied, very inconvenient) to six (e.g., very satisfied, very convenient). More satisfied the patient, better is the outcome. |
| Change in the Adoption at the clinic level | 6 months, 12 months | Adoption at the clinic level will be measured by a number of participants served using health records and examining nurses' adoption of intervention program through interviews |
| Change in the Adoption at the patient level measured by the Summary of Diabetes Self-Care Activities Scale | Baseline, 6 months, 12 months | Adoption at the patient level will be measured by the proportion of people adherent to the clinical advice in lifestyle and self-care. These will be measured by the self-reported Summary of Diabetes Self-Care Activities scale. Five areas are assessed by the scale: Diet, Exercise, Blood-glucose testing, Foot care, and Smoking status. Scale of 0-7 is used. Higher the score better is the outcome. |
| Change in lipid profile levels (HDL, LDL, Triglycerides, Total cholesterol) | Baseline, 6 months, 12 months | LDL and HDL will be measured using the elimination method (Dialab, Austria); triglyceride using GPO-PAP (Dialab, Austria); and total cholesterol using CHOD-PAP (Dialab, Austria) |
Contacts
Primary ContactBiraj M Karmacharya
Backup ContactRubee Dev
Outcome results
None listed